Health TrialsbyHealthPanel

Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics

ConditionsStereotactic RadiosurgerySpinal TumorRadiomicsPrognosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorZhuang Hongqing

About this trial

This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Patients who had spinal tumors and completed CT, MRI, PET-CT examination before and after stereotactic radiosurgery.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • No interventions

    Other intervention

    As this is a prognosis evaluation study, there are no interventions.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: spinal tumors, CT, MRI, PET-CT stereotactic radiosurgery1 intervention

Trial outcomes

Primary outcomes

1

PFS

progression-free survival

Time frame
1 years

Secondary outcomes

1

Overall survival (OS)

defined as the time from the beginning of diagnosis of spinal tumors to the death with any causes

Time frame
1 years
2

ORR

objective response rate

Time frame
3 months
3

DCR

disease control rate

Time frame
3 months
4

Recurrence free survival (RFS)

defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zhuang Hongqing

Lead sponsor

Peking University Third Hospital

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: